Drug analysis: Avastin

  • ID: 4462198
  • Drug Pipelines
  • 116 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF). The VEGF protein is an essential component of the angiogenesis pathway, critical for blood vessel formation, facilitating tumor growth, invasion, and metastasis. Inhibiting the VEGF protein leads to decreased blood vessel formation, thereby restricting nutrient intake and limiting tumor growth and development. The drug was first approved for colorectal cancer in 2004, and then went on to gain approvals for lung, brain, ovarian, cervical, and renal cell cancer indications.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Avastin: Colorectal cancer (CRC)
Avastin: Retinal disorders
Avastin: Ovarian cancer
Avastin: Glioblastoma (GBM)
Avastin: Renal cell cancer (RCC)
Avastin: Non-small cell lung cancer (NSCLC)
Avastin: Breast cancer: triple-negative
Avastin: Breast cancer: HR+/HER2-

List of Figures
Figure 1: Avastin for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of Avastin for colorectal cancer
Figure 3: Drug assessment summary of Avastin for colorectal cancer
Figure 4: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
Figure 5: Avastin for retinal disorders - SWOT analysis
Figure 6: Drug assessment summary for Avastin in retinal disorders
Figure 7: Drug assessment summary for Avastin in retinal disorders
Figure 8: Avastin for ovarian cancer - SWOT analysis
Figure 9: Drug assessment of Avastin for ovarian cancer
Figure 10: Drug assessment of Avastin for ovarian cancer
Figure 11: Avastin for glioblastoma - SWOT analysis
Figure 12: Drug assessment summary of Avastin in glioblastoma
Figure 13: Drug assessment summary of Avastin in glioblastoma
Figure 14: Avastin for renal cell cancer - SWOT analysis
Figure 15: Drug assessment summary of Avastin for renal cell cancer
Figure 16: Drug assessment summary of Avastin for renal cell cancer
Figure 17: Avastin for non-small cell lung cancer - SWOT analysis
Figure 18: Drug assessment summary for Avastin in non-small cell lung cancer
Figure 19: Drug assessment summary for Avastin in non-small cell lung cancer
Figure 20: Avastin for triple-negative breast cancer - SWOT analysis
Figure 21: Drug assessment summary of Avastin for triple-negative breast cancer
Figure 22: Drug assessment summary of Avastin for triple-negative breast cancer
Figure 23: Avastin for HR+/HER2- breast cancer - SWOT analysis
Figure 24: Drug assessment summary of Avastin in HR+/HER2- breast cancer
Figure 25: Drug assessment summary of Avastin in HR+/HER2- breast cancer

List of Tables
Table 1: Avastin drug profile
Table 2: Overview of major approvals for Avastin in colorectal cancer
Table 3: Avastin Phase III data in colorectal cancer
Table 4: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 5: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016-25
Table 6: Avastin drug profile
Table 7: Avastin late-phase trial data in retinal disorders
Table 8: Avastin ongoing late-phase clinical trial in retinal disorders
Table 9: Avastin drug profile
Table 10: Avastin pivotal trial data in ovarian cancer
Table 11: Avastin late-phase trial data in ovarian cancer
Table 12: Avastin ongoing Phase III clinical trials in ovarian cancer
Table 13: Avastin drug profile
Table 14: Avastin pivotal trial data in glioblastoma
Table 15: Avastin late-phase trial data in glioblastoma
Table 16: Avastin ongoing late-phase clinical trials in glioblastoma
Table 17: Avastin drug profile
Table 18: Avastin pivotal Phase III trial data in renal cell cancer
Table 19: Avastin drug profile
Table 20: Avastin pivotal trial data in non-small cell lung cancer
Table 21: Avastin late-phase trial data in non-small cell lung cancer
Table 22: Avastin drug profile
Table 23: Avastin pivotal trial data in triple-negative breast cancer
Table 24: Avastin late-phase trial data in triple-negative breast cancer
Table 25: Avastin drug profile
Table 26: Avastin pivotal trial data in HR+/HER2- breast cancer
Table 27: Avastin late-phase trial data in HR+/HER2- breast cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll